To test whether pathophysiological changes in colons resulted from NMS are a consequence of altered NGF signaling, neutralizing antibodies against NGF that block the binding of NGF to its receptor were administered intraperitoneally into NMS rats. The gene discussed is NGF; the disease is neuroleptic malignant syndrome.